EDP-182 Synthesis via Segmentation and Parameter Changes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective methods to synthesize 6,11-bridged macrocyclic erythromycin derivatives, such as EDP-182, which are active against MLSB-resistant bacteria while maintaining the stability, tolerance, and pharmacokinetics of macrolide antibiotics.
Innovation Solution
The process involves reacting specific compounds to produce O-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine as a key intermediate for the preparation of EDP-182, using palladium catalysts and various chemical reactions like hydrolysis, reduction, and oxidative cleavage, to achieve the desired macrocyclic structure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional macrolide antibiotics are used, then antibacterial activity is achieved, but resistance from MLSB-resistant strains develops
Solution Approach 1:
The macrolide molecule is divided into two distinct segments: the macrolide core structure (providing stability and pharmacokinetics) and the cladinose sugar moiety (providing antibacterial activity). This segmentation allows independent optimization of each segment's properties and enables replacement of the sugar with alternative compounds (like the benzo[d]oxazole derivative in EDP-182) to overcome resistance while maintaining core macrolide characteristics.
Solution Approach 2:
The patent modifies the chemical structure parameters of the cladinose sugar by replacing it with a benzo[d]oxazole ring system containing a hydroxylamine group. This structural parameter change creates EDP-182, which has enhanced binding affinity to ribosomal subunits of MLSB-resistant bacteria, thereby restoring efficacy against resistant strains while preserving the macrolide pharmacokinetic profile.
2Adaptability or versatility
If new macrolide derivatives are synthesized to overcome resistance, then efficacy against resistant strains is improved, but synthesis complexity increases
Solution Approach 1:
The patent employs preliminary action by using commercially available or easily synthesizable starting materials (erythromycin A, benzo[d]oxazole derivatives) and establishing a clear multi-step synthesis pathway. The sequence of reactions (acylation, cyclization, oxidation, reduction) is designed to build the complex hydroxylamine-containing structure from simpler precursors, making the overall synthesis process manageable and reproducible despite the structural complexity of the final product.
3Adaptability or versatility
If the cladinose sugar is replaced to enhance activity, then antibacterial spectrum is improved, but structural stability may be compromised
Solution Approach 1:
The patent creates a composite molecular structure where the stable macrolide core is combined with a chemically stable benzo[d]oxazole ring system. This composite structure (EDP-182) integrates the advantages of both components: the macrolide provides pharmacokinetic stability and bioavailability, while the benzo[d]oxazole derivative provides enhanced antibacterial activity and spectrum. The hydroxylamine group in the composite structure serves as a functional group that maintains stability while enabling active binding to bacterial ribosomes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the synthesis of EDP-182, providing enhanced antibacterial activity against MLSB-resistant strains while retaining the pharmacokinetic profile of macrolides.
Implementation Method 1
reacting a compound of formula (I) with a compound of formula (II) to produce a compound of formula (III), optionally in the presence of a palladium catalyst
Implementation Method 2
hydrolyzing a compound of formula (III) with aqueous acid to provide a compound of formula (IV)
Implementation Method 3
reducing a compound of formula (IV) with a reducing agent to provide a compound of formula (V)
Implementation Method 4
acylating a compound of formula (V) with an acylating agent to provide a compound of formula (VI)
Implementation Method 5
oxidatively cleaving a compound of formula (VI) with a cleaving reagent or reagents which are capable of performing oxidative cleavage to provide a compound of formula (VII)
Implementation Method 6
oxidizing a compound of formula (VII) with an oxidizing agent or agents to provide a compound of formula (VIII)
Data Source
AI summary
The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivative known as EDP-182 (IX-a). In particular, the present invention relates to processes and intermediates for the preparation of O-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine: